Parexel China Co.,Ltd.

Primary objectives: To evaluate the PK of 50 IU/kg rIX-FP in previously treated Chinese patients with hemophilia B (FIX activity ≤2%) in the single-dose PK phase; to evaluate the efficacy of routine prophylactic administration of rIX-FP in preventing spontaneous bleeding events in previously treated Chinese patients with hemophilia B (FIX activity ≤2%); to evaluate the safety of routine prophylactic administration of rIX-FP in the formation of FIX inhibitors in previously treated Chinese patients with hemophilia B (FIX activity ≤2%).

To evaluate the pharmacokinetic characteristics of Tigulixostat tablets (IBI128) after a single dose in healthy Chinese subjects

The primary objective of this study was to evaluate the safety and tolerability of ricolinostat in patients with signs and symptoms of CIPN. The exploratory objective was to evaluate the effect of ricolinostat treatment on the clinical manifestations of CIPN and IENFD.